All press releases

Alfasigma Streamlines Manufacturing Footprint to Sharpen Strategic Focus and Accelerate Innovation and Growth

Alfasigma Reports Solid Performance in 2025 Supported by Double-Digit Revenue Growth in key strategic brands in Immunology (+17%)[1], Gastroenterology (+15%), V...

Linerixibat approved for use in the U.S. for the treatment of cholestatic pruritus in primary biliary cholangitis (PBC)

GSK and Alfasigma announce agreement on worldwide rights for linerixibat

Alfasigma Secures Exclusive Rights from Innovative Molecules to Parenteral Adibelivir for Treatment of HSV Encephalitis, an Ultra-Rare Disease

Filgotinib Shows Positive Topline Results Across Full Spectrum of Axial Spondyloarthritis in OLINGUITO Phase 3 Study

Alfasigma Reports Record Growth in First-Ever Financial Results; €1.87 billion Revenue Setting the Stage for Future Growth

ALFASIGMA AT UEG WEEK (Vienna, 12 -15 OCTOBER 2024)

Alfasigma announces the Completion of Marketing Authorisation Transfer for Jyseleca® in the European Union

Alfasigma completes transaction to acquire the Jyseleca® business from Galapagos for up to €170 million